Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis

Detalhes bibliográficos
Autor(a) principal: Santos, Natalia Farias
Data de Publicação: 2023
Outros Autores: Osorio-de-Castro, Claudia Garcia Serpa, Sobreira-da-Silva, Mario Jorge
Tipo de documento: Artigo
Idioma: por
eng
spa
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3982
Resumo: Introduction: Cancer is one of the main causes of death in Brazil and worldwide. For each year of the triennium 2023-2025, 483,000 new cases are estimated for the country, except non-melanoma skin cancer, breast cancer being the most incident in women with 74,000 new cases. After the declaration of the COVID-19 pandemic by the World Health Organization, several Brazilian states determined restrictive measures to reduce the contamination and cancer diagnosis reference centers were impacted. Objective: To analyze the number of approved breast cancer chemotherapy procedures before and during the COVID-19 pandemic in SUS-affiliated cancer-care facilities in the State of Rio de Janeiro, Brazil. Method: Descriptive design, with time series and ecological analyses using publicly available data of chemotherapy procedures authorized by SUS between March 2018 and February 2021. Results: A total of 394,926 procedures were identified, an increase of 47% with a rising linear trend (R2=0,5203) during the period. Increases in hormonal receptor-positive cancer (46%) and in HER-2 positive carcinoma (900%) were observed. The patients travelled smaller distances for chemotherapy procedures. Conclusion: Results point out a possible effective response by the cancer care network and strengthening of the regionalization during the first pandemic year.
id INCA-1_3a3da0aa48b0d3c25a31d2bea5aa4168
oai_identifier_str oai:rbc.inca.gov.br:article/3982
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series AnalysisQuimioterapia para el Cáncer de Mama en el Estado de Río de Janeiro durante a la Pandemia de Covid-19: Análisis de Series de TiempoQuimioterapia para Câncer de Mama no Estado do Rio de Janeiro durante a Pandemia da Covid-19: Análise de Séries Temporaisantineoplásicosneoplasias da mamaCOVID-19serviço hospitalar de oncologiaantineoplastic agentsbreast neoplasmsCOVID-19oncology services, hospitalantineoplásicosneoplasias de la mamaCOVID-19servicio de oncología en hospitalIntroduction: Cancer is one of the main causes of death in Brazil and worldwide. For each year of the triennium 2023-2025, 483,000 new cases are estimated for the country, except non-melanoma skin cancer, breast cancer being the most incident in women with 74,000 new cases. After the declaration of the COVID-19 pandemic by the World Health Organization, several Brazilian states determined restrictive measures to reduce the contamination and cancer diagnosis reference centers were impacted. Objective: To analyze the number of approved breast cancer chemotherapy procedures before and during the COVID-19 pandemic in SUS-affiliated cancer-care facilities in the State of Rio de Janeiro, Brazil. Method: Descriptive design, with time series and ecological analyses using publicly available data of chemotherapy procedures authorized by SUS between March 2018 and February 2021. Results: A total of 394,926 procedures were identified, an increase of 47% with a rising linear trend (R2=0,5203) during the period. Increases in hormonal receptor-positive cancer (46%) and in HER-2 positive carcinoma (900%) were observed. The patients travelled smaller distances for chemotherapy procedures. Conclusion: Results point out a possible effective response by the cancer care network and strengthening of the regionalization during the first pandemic year.Introducción: El cáncer es una de las principales causas de muerte en el Brasil y en el mundo. Se estiman 483 000 nuevos casos en el país, para cada año del trienio 2023-2025, excluyendo el cáncer de piel no melanoma, siendo el cáncer de mama el más incidente en mujeres, con 74 000 nuevos casos. Luego de la declaración de la pandemia de covid-19 por la Organización Mundial de la Salud, varios Estados del Brasil establecieron medidas restrictivas con el objetivo de reducir la contaminación y los centros de referencia para el diagnóstico del cáncer fueron impactados. Objetivo: Analizar series de tiempo de las cantidades de procedimientos de quimioterapia aprobados para el cáncer de mama, antes y durante la pandemia de covid-19, en los establecimientos calificados para la alta complejidad en oncología en el Estado de Rio de Janeiro, Brasil. Método: Diseño descriptivo con análisis de series de tiempo y ecológico, utilizando datos públicos de procedimientos de quimioterapia aprobados por el Sistema Único de Salud entre marzo de 2018 y febrero de 2021. Resultados: Fueran identificados 394 926 procedimientos, representando un aumento de 47% con una tendencia lineal creciente (R2=0,5203) en el periodo. Fueron observados aumentos de procedimientos para cáncer de mama receptor hormonal positivo (46%) y carcinoma de mama HER-2 positivo (900%). Conclusión: Los resultados apuntan hacia una posible respuesta efectiva de la red de atención y fortalecimiento de la regionalización durante el primer año pandémico.Introdução: O câncer é uma das principais causas de morte no Brasil e no mundo. Estimam-se 483 mil novos casos no país, para cada ano do triênio 2023-2025, excetuando-se o câncer de pele não melanoma, sendo o câncer de mama o mais incidente em mulheres, com 74 mil novos casos. Após a declaração da pandemia da covid-19 pela Organização Mundial da Saúde, vários Estados brasileiros estabeleceram medidas restritivas, visando à redução da contaminação, e os centros de referência em diagnóstico do câncer foram impactados. Objetivo: Analisar séries temporais das quantidades de procedimentos aprovados de quimioterapia para câncer de mama antes e durante a pandemia da covid-19 nos estabelecimentos habilitados para alta complexidade em oncologia no Estado do Rio de Janeiro. Método: Estudo descritivo com análises de séries temporais e ecológica, usando dados públicos de procedimentos de quimioterapia autorizados pelo Sistema Único de Saúde entre março de 2018 e fevereiro de 2021. Resultados: Foram identificados 394.926 procedimentos, representando um aumento de 47% com tendência linear crescente (R2=0,5203) no período. Verificou-se um aumento de procedimentos para câncer de mama receptor hormonal positivo (46%) e carcinoma de mama HER-2 positivo (900%). Conclusão: Observou-se um aumento nos procedimentos de quimioterapia, assim como uma diminuição do deslocamento de tratamento dos grandes centros. Os resultados apontam para uma possível resposta efetiva da rede de atendimento e fortalecimento da regionalização durante o primeiro ano da pandemia.INCA2023-08-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfapplication/pdfapplication/pdftext/htmlhttps://rbc.inca.gov.br/index.php/revista/article/view/398210.32635/2176-9745.RBC.2023v69n3.3982Revista Brasileira de Cancerologia; Vol. 69 No. 3 (2023): July/Aug./Sept.; e-153982Revista Brasileira de Cancerologia; Vol. 69 Núm. 3 (2023): jul./ago./sept.; e-153982Revista Brasileira de Cancerologia; v. 69 n. 3 (2023): jul./ago./set.; e-1539822176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporengspahttps://rbc.inca.gov.br/index.php/revista/article/view/3982/3145https://rbc.inca.gov.br/index.php/revista/article/view/3982/3391https://rbc.inca.gov.br/index.php/revista/article/view/3982/3240https://rbc.inca.gov.br/index.php/revista/article/view/3982/3157Copyright (c) 2023 Revista Brasileira de Cancerologiahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSantos, Natalia FariasOsorio-de-Castro, Claudia Garcia SerpaSobreira-da-Silva, Mario Jorge2024-03-26T20:24:41Zoai:rbc.inca.gov.br:article/3982Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2024-03-26T20:24:41Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
Quimioterapia para el Cáncer de Mama en el Estado de Río de Janeiro durante a la Pandemia de Covid-19: Análisis de Series de Tiempo
Quimioterapia para Câncer de Mama no Estado do Rio de Janeiro durante a Pandemia da Covid-19: Análise de Séries Temporais
title Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
spellingShingle Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
Santos, Natalia Farias
antineoplásicos
neoplasias da mama
COVID-19
serviço hospitalar de oncologia
antineoplastic agents
breast neoplasms
COVID-19
oncology services, hospital
antineoplásicos
neoplasias de la mama
COVID-19
servicio de oncología en hospital
title_short Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
title_full Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
title_fullStr Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
title_full_unstemmed Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
title_sort Chemotherapy for Breast Cancer in the State of Rio de Janeiro during the COVID-19 Pandemic: Time Series Analysis
author Santos, Natalia Farias
author_facet Santos, Natalia Farias
Osorio-de-Castro, Claudia Garcia Serpa
Sobreira-da-Silva, Mario Jorge
author_role author
author2 Osorio-de-Castro, Claudia Garcia Serpa
Sobreira-da-Silva, Mario Jorge
author2_role author
author
dc.contributor.author.fl_str_mv Santos, Natalia Farias
Osorio-de-Castro, Claudia Garcia Serpa
Sobreira-da-Silva, Mario Jorge
dc.subject.por.fl_str_mv antineoplásicos
neoplasias da mama
COVID-19
serviço hospitalar de oncologia
antineoplastic agents
breast neoplasms
COVID-19
oncology services, hospital
antineoplásicos
neoplasias de la mama
COVID-19
servicio de oncología en hospital
topic antineoplásicos
neoplasias da mama
COVID-19
serviço hospitalar de oncologia
antineoplastic agents
breast neoplasms
COVID-19
oncology services, hospital
antineoplásicos
neoplasias de la mama
COVID-19
servicio de oncología en hospital
description Introduction: Cancer is one of the main causes of death in Brazil and worldwide. For each year of the triennium 2023-2025, 483,000 new cases are estimated for the country, except non-melanoma skin cancer, breast cancer being the most incident in women with 74,000 new cases. After the declaration of the COVID-19 pandemic by the World Health Organization, several Brazilian states determined restrictive measures to reduce the contamination and cancer diagnosis reference centers were impacted. Objective: To analyze the number of approved breast cancer chemotherapy procedures before and during the COVID-19 pandemic in SUS-affiliated cancer-care facilities in the State of Rio de Janeiro, Brazil. Method: Descriptive design, with time series and ecological analyses using publicly available data of chemotherapy procedures authorized by SUS between March 2018 and February 2021. Results: A total of 394,926 procedures were identified, an increase of 47% with a rising linear trend (R2=0,5203) during the period. Increases in hormonal receptor-positive cancer (46%) and in HER-2 positive carcinoma (900%) were observed. The patients travelled smaller distances for chemotherapy procedures. Conclusion: Results point out a possible effective response by the cancer care network and strengthening of the regionalization during the first pandemic year.
publishDate 2023
dc.date.none.fl_str_mv 2023-08-18
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3982
10.32635/2176-9745.RBC.2023v69n3.3982
url https://rbc.inca.gov.br/index.php/revista/article/view/3982
identifier_str_mv 10.32635/2176-9745.RBC.2023v69n3.3982
dc.language.iso.fl_str_mv por
eng
spa
language por
eng
spa
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/3982/3145
https://rbc.inca.gov.br/index.php/revista/article/view/3982/3391
https://rbc.inca.gov.br/index.php/revista/article/view/3982/3240
https://rbc.inca.gov.br/index.php/revista/article/view/3982/3157
dc.rights.driver.fl_str_mv Copyright (c) 2023 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Revista Brasileira de Cancerologia
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
text/html
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 69 No. 3 (2023): July/Aug./Sept.; e-153982
Revista Brasileira de Cancerologia; Vol. 69 Núm. 3 (2023): jul./ago./sept.; e-153982
Revista Brasileira de Cancerologia; v. 69 n. 3 (2023): jul./ago./set.; e-153982
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042238984814592

Registros relacionados